Yoshida K, Sakamoto S, Sumi S, Higashi Y, Kitahara S
Department of Urology, Dokkyo University School of Medicine, Tochigi, Japan.
Cancer. 1998 Aug 15;83(4):760-6. doi: 10.1002/(sici)1097-0142(19980815)83:4<760::aid-cncr19>3.0.co;2-q.
Telomerase activity has been shown to be increased in numerous tumors and cell lines, although to the authors' knowledge there has been no previous assessment of telomerase activity in renal cell carcinoma (RCC). To examine whether telomerase activity could be used as a biochemical parameter for predicting the behavior of RCC, telomerase activity was quantified in RCC samples and correlated with clinicopathologic findings.
Telomerase activity was quantified in 50 RCC samples and 21 samples of normal renal tissue using fluorescence-based telomeric repeat amplification.
Telomerase activity was detected in 28 of 50 RCC samples (mean +/- standard deviation, 35.03 +/- 18.47 U/microg protein), whereas there was no telomerase activity in 21 normal renal tissue specimens. Telomerase activity in tumors classified as pT4 was significantly higher than in tumors classified as pT1 to pT3. Telomerase activity also correlated with patient age.
Telomerase activity was increased in RCC samples compared with normal renal tissues. Although significant associations were observed between telomerase activity and clinicopathologic parameters, further study is required to determine whether telomerase activity affects the biologic and clinical behavior of RCC.
尽管据作者所知，此前尚无关于肾细胞癌（RCC）端粒酶活性的评估，但已表明端粒酶活性在众多肿瘤和细胞系中升高。为了研究端粒酶活性是否可作为预测RCC行为的生化参数，对RCC样本中的端粒酶活性进行了定量，并与临床病理结果进行了关联分析。
使用基于荧光的端粒重复序列扩增技术，对50份RCC样本和21份正常肾组织样本中的端粒酶活性进行定量。
在50份RCC样本中的28份检测到端粒酶活性（平均±标准差，35.03±18.47 U/μg蛋白），而21份正常肾组织标本中未检测到端粒酶活性。分类为pT4的肿瘤中端粒酶活性显著高于分类为pT1至pT3的肿瘤。端粒酶活性还与患者年龄相关。
与正常肾组织相比，RCC样本中的端粒酶活性升高。尽管端粒酶活性与临床病理参数之间存在显著关联，但仍需进一步研究以确定端粒酶活性是否影响RCC的生物学和临床行为。
